AGI Therapeutics plc : Offer Update

AGI Therapeutics plc

("AGI" or the "Company")

Offer Update

01 March 2012

Aravis Therapeutics Limited ("Aravis") announced on 03 February 2012 that it had declared its Offer unconditional in all respects and it intended to exercise its rights under the provisions of Section 204 of the Irish Companies Act 1963 to acquire compulsorily all outstanding AGI Shares not acquired or agreed to be acquired pursuant to the Offer on the same terms as the Offer.

On 28 February 2012 Aravis issued statutory notices pursuant to section 204(1) of the Companies Act 1963 to those AGI Shareholders who had not yet validly accepted the Offer.

In accordance with section 204(1) of the Companies Act 1963, unless upon an application made to the Court by any AGI Shareholders who have not yet validly accepted the Offer, on or before 28 March 2012, the Court thinks fit to order otherwise, Aravis will be entitled and bound to compulsorily acquire the AGI Shares held by those Shareholders.

As notified pursuant to section 67 of the Companies Act 1990, as at 16 February 2012, Aravis holds 60,784,191 shares representing approximately 90.17 per cent of the issued share capital of the Company.

As announced on 03 February 2012, the last day of trading of AGI Shares on ESM and AIM will be close of business today and cancellation of admission to trading on ESM and AIM will take effect from 7.00 a.m. tomorrow, Friday 02 March 2012.

Capitalised terms used in this announcement shall bear the same meaning as in the Offer Document, unless the context requires otherwise.

Enquiries:

AGI Therapeutics plc	Tel:      [phone]
David Kelly, CFO
Davy Corporate Finance	Tel:      [phone]
Financial adviser to AGI
John Frain
David Nangle
Goodbody Corporate Finance	Tel:      [phone]
Financial adviser to the Aravis Group
Simon Howley
Stephen Kane